X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9073) 9073
Book Review (2085) 2085
Publication (883) 883
Book Chapter (29) 29
Conference Proceeding (25) 25
Dissertation (7) 7
Magazine Article (7) 7
Web Resource (4) 4
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bevacizumab (7751) 7751
index medicus (7415) 7415
humans (7295) 7295
female (4497) 4497
oncology (3910) 3910
male (3741) 3741
middle aged (3491) 3491
aged (3337) 3337
adult (2400) 2400
chemotherapy (2386) 2386
cancer (2300) 2300
treatment outcome (2239) 2239
ophthalmology (2114) 2114
angiogenesis inhibitors - therapeutic use (2003) 2003
endothelial growth-factor (1921) 1921
antineoplastic combined chemotherapy protocols - therapeutic use (1902) 1902
antibodies, monoclonal, humanized (1877) 1877
vascular endothelial growth factor (1783) 1783
vascular endothelial growth factor a - antagonists & inhibitors (1734) 1734
angiogenesis inhibitors - adverse effects (1634) 1634
care and treatment (1634) 1634
aged, 80 and over (1529) 1529
angiogenesis inhibitors - administration & dosage (1367) 1367
angiogenesis (1334) 1334
therapy (1249) 1249
antineoplastic combined chemotherapy protocols - adverse effects (1234) 1234
medicine & public health (1181) 1181
ranibizumab (1180) 1180
antibodies, monoclonal - adverse effects (1106) 1106
retrospective studies (1083) 1083
antibodies, monoclonal, humanized - administration & dosage (1064) 1064
metastasis (1060) 1060
antibodies, monoclonal - therapeutic use (1058) 1058
disease-free survival (1055) 1055
drug therapy (1049) 1049
research (1033) 1033
antibodies, monoclonal - administration & dosage (1032) 1032
macular degeneration (1029) 1029
colorectal cancer (994) 994
intravitreal injections (991) 991
colorectal neoplasms - drug therapy (985) 985
pharmacology & pharmacy (950) 950
antibodies, monoclonal, humanized - adverse effects (939) 939
angiogenesis inhibitors (924) 924
trial (912) 912
clinical trials (901) 901
antineoplastic agents - therapeutic use (872) 872
antibodies, monoclonal, humanized - therapeutic use (868) 868
follow-up studies (805) 805
survival (788) 788
analysis (768) 768
antineoplastic agents (766) 766
animals (761) 761
hematology, oncology and palliative medicine (756) 756
antimitotic agents (738) 738
patients (729) 729
vegf (728) 728
colorectal neoplasms - pathology (705) 705
combination (693) 693
surgery (689) 689
fluorouracil (680) 680
tomography, optical coherence (659) 659
lung neoplasms - drug therapy (636) 636
paclitaxel (629) 629
risk factors (623) 623
health aspects (621) 621
prospective studies (619) 619
eye diseases (613) 613
neoplasm metastasis (607) 607
bevacizumab - administration & dosage (605) 605
tumors (603) 603
oxaliplatin (601) 601
antineoplastic agents - adverse effects (594) 594
1st-line treatment (593) 593
leucovorin (593) 593
antineoplastic combined chemotherapy protocols - administration & dosage (591) 591
phase-ii trial (584) 584
phase-iii trial (573) 573
metastatic colorectal-cancer (565) 565
prognosis (558) 558
neoplasm staging (557) 557
fluorouracil - administration & dosage (554) 554
cancer therapies (544) 544
fluorescein angiography (542) 542
safety (530) 530
efficacy (528) 528
irinotecan (525) 525
carcinoma, non-small-cell lung - drug therapy (518) 518
abridged index medicus (515) 515
studies (515) 515
cetuximab (491) 491
visual acuity (491) 491
avastin (484) 484
breast neoplasms - drug therapy (481) 481
genetic structures (475) 475
intravitreal bevacizumab (475) 475
double-blind (474) 474
drug administration schedule (471) 471
neovascularization (471) 471
bevacizumab - therapeutic use (470) 470
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8721) 8721
Japanese (98) 98
French (92) 92
German (90) 90
Spanish (25) 25
Korean (24) 24
Chinese (18) 18
Polish (10) 10
Italian (8) 8
Russian (7) 7
Czech (3) 3
Hungarian (3) 3
Dutch (1) 1
Indonesian (1) 1
Portuguese (1) 1
Slovenian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


08/2011
Background: Bevacizumab a recombinant humanized monoclonal antibody was approved in 2004 by US FDA for metastatic colorectal cancer. It is reported to cause... 
adverse effect | serum calcium | tetany | Bevacizumab
Web Resource
Journal Article
ACTA GASTRO-ENTEROLOGICA BELGICA, ISSN 1784-3227, 04/2019, Volume 82, Issue 2, pp. 322 - 325
Colorectal cancer is one of the most frequently diagnosed malignancies worldwide. One of the most important developments in the management of metastatic... 
bowel ischaemia | GASTROINTESTINAL PERFORATION | metastatic colorectal cancer | RISK | GASTROENTEROLOGY & HEPATOLOGY | gastro-intestinal bleeding | Bevacizumab
Journal Article
Journal Article
JAMA, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Randomization | Oxaliplatin | Monoclonal antibodies | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, pp. CD007419 - CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor... 
CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Randomized Controlled Trials as Topic | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | Quality of Life | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 20, pp. 1925 - 1936
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2015, Volume 33, Issue 1, pp. 13 - 21
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9807, pp. 1931 - 1939
Journal Article